SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and

Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System   Demonstrated 100 Percent Agreement with Authorized Nasopharyngeal Assays SOUTH SAN FRANCISCO, Calif. , Aug.

Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay Fluidigm Selected for $37 Million Project under

License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging Systems SOUTH SAN FRANCISCO, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to

Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies SOUTH SAN FRANCISCO, Calif. , July 31, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative

Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs Adopting the Fluidigm   High-Throughput Testing Model SOUTH SAN FRANCISCO, Calif., and COLUMBUS, Ohio ,

SOUTH SAN FRANCISCO, Calif. , July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2020 financial results on Thursday,

Tracking the Immune Response of Patients Hospitalized with COVID-19 in 10 Research Sites Across the United States Study May Inform Recommendations for COVID-19 Care, New Strategies for Treatments SOUTH SAN FRANCISCO, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an

iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening End-to-End Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Screening of Critical Populations Under Way , Capacity of Up to 6,000 Tests Per Day on Single Instrument

Fluidigm to Be Exclusive Distributor for Bethyl Antibodies for Use with Imaging Mass Cytometry Providing Researchers with Expanded Capabilities in Interrogating the Tissue Microenvironment SOUTH SAN FRANCISCO, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an